Skip to main content

Table 5 Sensitivity analyses

From: Economic evaluation of increasing population rates of cardiac catheterization

Parameter Incremental cost-effectiveness ratio ($ per QALY)
  ACS
(Yusuf RR)
ACS
(FRISC-II RR)
Non-ACS
Base case $23,559 $31,438 $32,107
ACS specific yield (2.6:1 for males, 3.4:1 for females) $22,187 $30,768  
Non-ACS specific yield (2.5:1 for males, 5:1 for females)    $29,593
Disease yield for males (cost per QALY for male subgroup)    
   Decreased to 4:1 catheterizations per high risk case detected $28,335 $34,139 $34,673
   Increased to 2:1 catheterizations per high risk case detected $21,973 $32,167 $25,466
Disease yield for females (cost per QALY for female subgroup)    
   Decreased to 7:1 catheterizations per high risk case detected $22,485 $27,626 $51,189
   Increased to 3:1 catheterizations per high risk case detected $17,410 $24,944 $32,390
Relative risk of death associated with medical management compared to revascularisation    
   Increase by 25% (revascularization more beneficial) $13,300 $18,717 $17,884
   Decrease by 25% (revascularization less beneficial) Dominated $196,414 Dominated
Use of Seattle Angina Questionnaire disease specific quality of life measure $20,975 $27,575 $26,264
Procedural Costs    
   Increase by 50% $30,631 $41,228 $40,540
   Decrease by 25% $16,486 $21,648 $23,674
Costs of care    
   Increase by 50% $21,193 $27,577 $31,294
   Decrease by 25% $24,741 $33,368 $32,513
Discount rate    
   No discounting $12,324 $15,388 $12,672
   3% discount rate $19,300 $25,307 $24,276
   6% discount rate $25,617 $34,389 $35,971